Profile data is unavailable for this security.
About the company
Elekta AB (publ) is a Sweden-based medical technology company which aims to improve, prolong and save lives through clinical solutions for treating cancer and brain disorders. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. Elekta AB (publ) develops clinical treatment solutions for radiation therapy and radiosurgery, as well as work flow-enhancing software systems, across the spectrum of cancer care. The Company provides clinical solutions for image guided radiation therapy and stereotactic radiosurgery, giving oncologists and neurosurgeons an unmatched capability to treat tumors and functional targets with ultra-high precision while sparing healthy tissue.
- Revenue in SEK (TTM)18.02bn
- Net income in SEK237.00m
- Incorporated1972
- Employees4.54k
- LocationElekta AB (publ)Kungstensgatan 18STOCKHOLM 113 57SwedenSWE
- Phone+46 858725400
- Fax+46 858725500
- Websitehttps://www.elekta.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arjo AB (publ) | 11.26bn | 430.00m | 8.94bn | 7.00k | 22.27 | 1.27 | 5.83 | 0.7933 | 1.58 | 1.58 | 41.36 | 27.67 | 0.7186 | 4.64 | 6.54 | 1,570,333.00 | 2.74 | 3.58 | 3.72 | 5.45 | 43.46 | 43.97 | 3.81 | 5.35 | 0.8874 | 4.96 | 0.431 | 44.32 | 2.84 | 4.82 | 3.75 | 4.32 | -12.31 | 7.89 |
| RaySearch Laboratories AB (publ) | 1.27bn | 223.62m | 10.46bn | 422.00 | 56.06 | 13.59 | 24.00 | 8.26 | 6.52 | 6.52 | 36.93 | 26.89 | 0.6144 | 8.17 | 3.14 | 3,044,546.00 | 10.85 | 2.96 | 16.36 | 4.37 | 91.88 | 90.93 | 17.66 | 5.80 | 1.52 | 217.60 | 0.3277 | 67.90 | 16.62 | 9.96 | 149.49 | 32.19 | 0.5132 | -- |
| Biotage AB | 1.96bn | 255.00m | 11.44bn | 622.00 | 44.90 | 2.97 | 26.30 | 5.83 | 3.18 | 3.18 | 24.48 | 48.05 | 0.398 | 1.66 | 7.44 | 2,913,819.00 | 5.18 | 8.47 | 5.86 | 9.93 | 62.62 | 61.62 | 13.00 | 15.07 | 1.56 | 24.71 | 0.0583 | 48.01 | 9.83 | 13.30 | 15.45 | 8.74 | 30.04 | -- |
| ChemoMetec A/S | 691.76m | 254.52m | 13.77bn | 184.00 | 54.08 | 15.29 | 48.76 | 19.90 | 9.72 | 9.72 | 26.41 | 34.36 | 0.6943 | 0.7315 | 6.34 | 2,656,324.00 | 25.55 | 27.96 | 30.43 | 35.10 | 80.06 | 79.57 | 36.79 | 35.02 | 2.92 | -- | 0.0128 | 144.08 | -8.22 | 18.37 | -23.72 | 26.64 | 9.97 | -11.81 |
| Elekta AB (publ) | 18.02bn | 237.00m | 17.75bn | 4.54k | 77.59 | 2.09 | 11.54 | 0.9853 | 0.6207 | 0.6207 | 47.15 | 23.04 | 0.5967 | 3.73 | 3.05 | 3,972,002.00 | 0.7915 | 3.48 | 1.41 | 6.21 | 37.80 | 38.22 | 1.33 | 6.02 | 0.8634 | 6.71 | 0.461 | 92.20 | -0.5685 | 4.29 | -81.80 | -26.22 | 15.56 | 5.92 |
| Vitrolife AB | 3.61bn | 498.00m | 19.23bn | 1.15k | 38.65 | 1.47 | 20.44 | 5.33 | 3.67 | 3.67 | 26.63 | 96.91 | 0.2154 | 3.64 | 5.97 | 3,222,322.00 | 2.97 | -3.38 | 3.08 | -3.52 | 59.32 | 58.06 | 13.80 | -17.40 | 3.08 | 8.14 | 0.1294 | -- | 2.76 | 19.51 | 113.32 | 6.03 | 18.32 | -- |
| AddLife AB | 10.44bn | 337.00m | 20.72bn | 2.32k | 63.57 | 4.07 | 17.93 | 1.98 | 2.77 | 2.77 | 85.69 | 43.22 | 0.8102 | 3.78 | 5.64 | 4,628,546.00 | 2.63 | 4.45 | 3.92 | 7.00 | 37.79 | 37.39 | 3.25 | 5.13 | 0.5125 | 3.07 | 0.4886 | 33.59 | 6.21 | 24.21 | 32.63 | 12.38 | 28.28 | 8.45 |
| Embla Medical hf | 8.31bn | 699.21m | 21.00bn | 4.08k | 30.05 | 2.71 | 16.76 | 2.53 | 1.09 | 1.09 | 12.88 | 12.03 | 0.5475 | 2.14 | 6.69 | 1,353,731.00 | 4.64 | 3.77 | 5.48 | 4.42 | 63.19 | 62.22 | 8.47 | 6.60 | 1.10 | 4.85 | 0.3973 | 0.00 | 8.81 | 4.49 | 16.94 | 0.6688 | 4.25 | -- |
Data as of Jul 18 2025. Currency figures normalised to Elekta AB (publ)'s reporting currency: Swedish Krona SEK
39.57%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 30 Jun 2024 | 34.76m | 9.43% |
| T. Rowe Price Associates, Inc. (IM)as of 25 Feb 2025 | 18.56m | 5.04% |
| Nordea Investment Management ABas of 30 Apr 2025 | 15.15m | 4.11% |
| SEB Investment Management ABas of 30 May 2025 | 15.08m | 4.09% |
| Lannebo Kapitalf�rvaltning AB (Sweden)as of 30 Jun 2025 | 14.50m | 3.94% |
| The Vanguard Group, Inc.as of 02 Jul 2025 | 12.86m | 3.49% |
| Carnegie Fonder ABas of 30 Jun 2025 | 9.74m | 2.64% |
| T. Rowe Price International Ltd.as of 31 Mar 2025 | 9.20m | 2.50% |
| Indecap Fonder ABas of 30 Jun 2025 | 8.77m | 2.38% |
| Handelsbanken Fonder ABas of 30 Jun 2025 | 7.23m | 1.96% |
More ▼
Data from 31 Mar 2025 - 30 Jun 2025Source: FactSet Research Systems Inc.
